UCB Governance
The Company is administered by a Board of Directors and run by an Executive Committee, whose respective functions and responsibilities are clearly defined in the Corporate Governance Charter.
UCB SA/NV has adopted the 2020 edition of the Belgian Code of Corporate Governance as its reference Code taking into account the specific international aspects of the Company. As part of these rules, UCB SA/NV, as a listed company, has adopted a Corporate Governance Charter and a Code of Conduct, including a Dealing Code.
The Corporate Governance Charter established by the Board of Directors aims at providing a comprehensive and transparent disclosure of the Company’s governance. It defines the system of checks and balances between the shareholders/investors, the Board and the management to shape an efficiently functioning company, ideally geared to produce long-term sustainable value for all the Company’s stakeholders. It will be continuously updated as required.
Articles of Association
Special Reports of the Board
Remuneration Policy
Related Press Releases
Corporate governance charter

Dealing code

Code of conduct

Board of Directors
To enhance the overall effectiveness of the Board by ensuring focus, oversight and monitoring of sensitive areas, the Board has created three specialist committees.

the Audit Committee
The Audit Committee assists the Board in its responsibility of monitoring the management of UCB and the UCB Group as a whole.
3 members (67% independent):
- Jonathan Peacock (Chair & Independent Director)
- Viviane Monges (Independent Director)
- Charles-Antoine Janssen (Director)
the Governance, Remuneration and Nomination Committee (GNCC)
The Governance, Remuneration and Nomination Committee (GNCC) ensures that the appointment and re-election process is organized objectively and professionally and proposes the remuneration policy for non-executive Directors and executive managers.
3 members (67% independent):
- Fiona du Monceau (Chair)
- Pierre Gurdjian (Independent Director)
- Kay Davies (Independent Director)
the Scientific Committee
The Scientific Committee assists the Board when reviewing the quality of UCB’s R&D science and its competitive standing. It assesses the strategy proposed by UCB’s management in R&D matters and communicates its recommendations to the Board.
2 members (100% independent):
- Kay Davies (Chair and Independent Director),
- Susan Gasser (Independent Director).
Composition
(Updated: December 2022)
13 Members
7 Independent Directors (54%)
6 Nationalities
5 Women (38%)
4-Year Mandate
Age Limit: 70
Jonathan Peacock

Independent Director
Chair of the Board
Chair of the Audit Committee
First appointed in 2021
End of term in 2025
Fiona du Monceau

Director
Vice-chair of the Board
Chair of the GNCC
First appointed in 2021
End of term in 2025
Jean-Christophe Tellier

Executive Director
First appointed in 2014
End of term in 2026
Jan Berger

Independent Director
First appointed in 2019
End of term in 2027
Maëlys Castella

Independent Director
Member of the Audit Committee
First appointed in 2023
End of term in 2027
Kay Davies

Independent Director
Chair of the Scientific Committee
Member of the GNCC
First appointed in 2014
End of term in 2026
Albrecht De Graeve

Director
First appointed in 2010
End of term in 2025
Susan Gasser

Independent Director
Member of the Scientific Committee
First appointed in 2021
End of term in 2025
Pierre Gurdjian

Independent Director
Member of the GNCC
First appointed in 2016
End of term in 2024
Charles-Antoine Janssen

Director
Member of the Audit Committee
First appointed in 2012
End of term in 2024
Cyril Janssen

Director
First appointed in 2015
End of term in 2027
Cédric van Rijckevorsel

Director
First appointed in 2014
End of term in 2026
Ulf Wiinberg

Independent Director
First appointed in 2016
End of term in 2024
Honorary directors
- Karel Boone, Honorary Chair
- Evelyn du Monceau, Honorary Chair
- Mark Eyskens, Honorary Chair
- Georges Jacobs de Hagen, Honorary Chair
- Daniel Janssen, Honorary Deputy Chair
- Gerhard Mayr, Honorary Chair
- Prince Lorenz of Belgium
- Alan Blinken
- Alice Dautry
- Arnoud de Pret
- Roch Doliveux
- Peter Fellner
- Guy Keutgen
- Jean-Pierre Kinet
- Tom McKillop
- Gaëtan van de Werve
- Jean-Louis Vanherweghem
- Bridget van Rijckevorsel
- Norman J. Ornstein
Executive Committee
We have adapted an organizational structure on four pillars around which we create value for each patient, centered by our focus and integrated across functional teams around different patient populations.

Composition
(Updated: April 2023)
9 members
5 nationalities
4 women (44%)
Jean-Christophe Tellier

Chief Executive Officer &
Chairman of the Executive Committee
Joined UCB in 2011
Appointed CEO in 2015
Emmanuel Caeymaex

Executive Vice President
Immunology Solutions & Head of U.S.
Joined UCB in 1994
Appointed in 2015
Sandrine Dufour

Executive Vice President
Chief Financial Officer
Joined UCB in July 2020
Appointed in July 2020
Jean Luc Fleurial

Executive Vice President
Chief Human Resources Officer
Joined UCB in 2017
Appointed in 2017
Iris Löw-Friedrich

Executive Vice President
Chief Medical Officer
Joined UCB in 2006
Appointed in 2008
Kirsten Lund-Jurgensen

Executive Vice President
Supply & Technology Solutions
Joined UCB in 2019
Appointed in 2019
Dhaval Patel

Executive Vice President &
Chief Scientific Officer
Joined UCB in 2017
Appointed in 2017
Charl van Zyl

Executive Vice President
Neurology Solutions & Head of EU /International
Joined UCB in 2017
Appointed in 2017
Denelle J. Waynick Johnson

Executive Vice President &
General Counsel
Joined UCB in 2023
Appointed in 2023
Shareholders and Shareholder Meetings
Find out about UCB shareholders, their transparency notifications and our shareholder meetings on the dedicated webpage.